Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ktn3379 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Celldex Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KTN3379 + trastuzumab is a combination of two monoclonal antibodies targeting receptor tyrosine kinases implicated in cancer cell growth and treatment resistance. **KTN3379** is a fully human anti-ErbB3 monoclonal antibody with engineered YTE half-life extension, locking ErbB3 in an inactive configuration to inhibit tumor growth and overcome resistance mechanisms. **Trastuzumab** is a recombinant humanized IgG1 monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2/ERBB2), inhibiting downstream signaling pathways responsible for cancer cell proliferation and survival. This combination is designed to block both ErbB3 and HER2 signaling in HER-family driven cancers, notably overcoming resistance to anti-HER2 therapies. KTN3379 was developed by Kolltan Pharmaceuticals, and the combination has been studied in phase 1b clinical trials for safety, pharmacokinetics, and preliminary efficacy in various solid tumors[1][3][5].
- Brand names
- HerceptinHerzumaOntruzantOgivriKanjintiTrazimeraZercepacHercessi
- Other names
- ktn3379 + trastuzumab
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ktn3379 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ktn3379 + trastuzumab.